All publications

GELUCIRE® 4414 for type IV lipid based formulations and their in vitro in vivo performance evaluation

  • Poster

AAPS PharmSci360 – Philadelphia (USA)  - 2021

In this study, Gelucire® 44/14 in type IV lipid-based formulation has been evaluated to increase the solubility and in vivo performance of ticagrelor. 

Gelucire 48/16® for Type-IV Lipid Based Formulations and Their In Vitro In Vivo Performance Evaluation

  • Poster

AAPS PharmSci360 – San Antonion (USA)  - Nov 2019

Agnivesh Shrivastava, Ketkee Deshmukh, Sunil Bambarkar, Nabil Farah, Kavita Singh

Understanding The Role Of In Vitro And In Vivo Evaluation Techniques In Determining the Performance of Lipid-Based Formulations

  • Poster

CRS Annual Meeting – Valencia (Spain)  - Jul 2019

Ketkee DESHMUKH, Agnivesh SHRIVASTAVA, Sunil BAMBARKAR, Nabil FARAH, Kavita SINGH

In this case study using curcuminoids as model drug, the authors show that in vitro lipolysis test is a useful tool to predict in vivo performance 

Gelucire 48/16®: A Versatile Non-Ionic Solid Solubilizer for Tablets of Poorly Water-Soluble Drugs

  • Poster

AAPS PharmSci360 – Washington DC (USA)  - Nov 2018

Agnivesh Shrivastava, Ketkee Deshmukh, Nabil Farah, Sharda Gurram, Sunil Bambarkar

A solid dispersion of ticagrelor and Gelucire® 48/16 is prepared to increase drug solubility . The solid dispersion is converted into tablets. The formulated tablets showed improved dissolution rate compared to the market reference. 

Bioavailable Curcumin – A Type 4 Lipid Based Drug Delivery System Using Gelucire®48/16 As Solid Solubilizer

  • Poster

CRS Annual Meeting – New York (USA)  - Jul 2018

Ketkee Deshmukh, Sharda Gurram, Sunil Bambarkar, Vincent Jannin, Nabil Farah, Kavita Singh

Formulation of a self-emulsifying lipid formulation of curcumin

  • Poster

AAPS Annual Meeting & Exposition – San Diego (USA)  - 2014

Vincent Jannin, Camille Dumont, Hamza Benhaddou, Stéphanie Chevrier, Yann Chavant, Christophe Voutsinas, Frédéric Demarne

Characterization of a new self-emulsifying excipient to expand formulation options for poorly soluble drugs: Gelucire® 48/16

  • Poster

AAPS Annual Meeting & Exposition – Chicago (USA)  - Oct 2012

V. JANNIN, M. DI CUIA, S. CHEVRIER, A. FAURE, Y. CHAVANT, C. VOUTSINAS, F. DEMARNE